Data Horizon Corporation (3628.T) Surges 14.8% on Healthcare Data Demand

Data Horizon Corporation (3628.T) delivered a strong performance on the JPX, with 3628.T stock surging 14.8% to close at ¥660 on May 20, 2026. The healthcare information services provider, which operates as a subsidiary of DeNA Co., Ltd., saw robust trading activity with volume reaching 107,000 shares—more than triple its average daily volume of 32,819. The stock now trades above its 50-day average of ¥497.78 and 200-day average of ¥527.66, signaling sustained upward momentum. This rally reflects growing investor confidence in Japan’s medical data services sector.

Strong Price Action and Technical Momentum

3628.T stock opened at ¥647 and climbed steadily throughout the session, hitting an intraday high of ¥665. The ¥85 gain represents the largest single-day move in recent weeks, pushing the stock closer to its 52-week high of ¥679. Technical indicators confirm the bullish setup: RSI stands at 70.23 (overbought territory), MACD histogram shows positive divergence at 19.96, and ADX reads 32.65, indicating a strong uptrend.

Volume surged dramatically, with 107,000 shares traded versus the 30-day average of 32,819. This 226% spike in volume validates the price move and suggests institutional buying interest. The stock now sits in the upper half of its 52-week range (¥422 to ¥679), demonstrating recovery from earlier weakness.

Healthcare Sector Tailwinds and Market Position

Data Horizon operates in Japan’s Medical – Healthcare Information Services industry, a defensive segment benefiting from demographic shifts and digital health adoption. The company provides medical information services, generic drug notification systems, and health business support platforms to Japanese insurers. With 374 full-time employees and headquarters in Hiroshima, the firm has built a specialized niche in healthcare data.

The Healthcare sector on JPX trades at an average P/E of 23.19 and shows 1.76% six-month performance. Data Horizon’s market cap of ¥8.24 billion positions it as a smaller player but with unique data assets. The company’s focus on insurer relationships provides recurring revenue stability in a sector increasingly dependent on data analytics.

Financial Metrics and Valuation Concerns

3628.T trades at a P/E ratio of 30.73 and price-to-sales of 1.60, both elevated relative to sector averages. The stock carries a debt-to-equity ratio of 11.10, reflecting significant leverage that warrants caution. Free cash flow per share stands at -¥12.18, indicating the company burns cash operationally. Revenue per share reached ¥405.10, while net income per share was ¥21.12 trailing twelve months.

Meyka AI rates 3628.T with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s ROE of 98.95% appears inflated due to negative tangible book value, a red flag for balance sheet quality. These grades are not guaranteed and we are not financial advisors.

Price Forecast and Investment Outlook

Meyka AI’s forecast model projects ¥608.30 as the yearly price target, implying 7.9% downside from current levels. The quarterly forecast sits at ¥490.41, while the three-year projection drops to ¥174.80, suggesting significant long-term headwinds. Track 3628.T on Meyka for real-time updates and analyst coverage changes.

The company faces earnings announcement on August 7, 2026, which could provide clarity on operational trends. Current technical overbought conditions (RSI 70.23) suggest near-term consolidation risk. Investors should monitor cash flow trends and debt management closely, as the high leverage and negative free cash flow present structural challenges despite today’s rally.

Final Thoughts

Data Horizon Corporation’s 14.8% surge reflects short-term momentum in Japan’s healthcare data sector, but fundamental concerns persist. The company’s elevated valuation multiples, high debt burden, and negative free cash flow create downside risks despite strong technical indicators. While the healthcare information services niche offers defensive characteristics, investors should await Q2 earnings results before committing capital. The Meyka AI B-grade rating and bearish long-term price forecasts suggest caution at current levels.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.